X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA CIPLA PLETHICO PHARMA/
CIPLA
 
P/E (TTM) x -1.1 40.5 - View Chart
P/BV x 0.0 3.7 0.4% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PLETHICO PHARMA   CIPLA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
CIPLA
Mar-18
PLETHICO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs395663 59.6%   
Low Rs31479 6.5%   
Sales per share (Unadj.) Rs604.4189.0 319.7%  
Earnings per share (Unadj.) Rs32.517.6 184.6%  
Cash flow per share (Unadj.) Rs51.334.0 150.8%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs473.6176.7 267.9%  
Shares outstanding (eoy) m34.08805.12 4.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.43.0 11.7%   
Avg P/E ratio x6.632.5 20.2%  
P/CF ratio (eoy) x4.216.8 24.7%  
Price / Book Value ratio x0.53.2 13.9%  
Dividend payout %017.1 0.0%   
Avg Mkt Cap Rs m7,262459,724 1.6%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m1,59626,901 5.9%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m20,598152,193 13.5%  
Other income Rs m3863,577 10.8%   
Total revenues Rs m20,984155,769 13.5%   
Gross profit Rs m2,81828,264 10.0%  
Depreciation Rs m64213,228 4.9%   
Interest Rs m1,5931,142 139.5%   
Profit before tax Rs m96917,470 5.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m-1382,501 -5.5%   
Profit after tax Rs m1,10714,166 7.8%  
Gross profit margin %13.718.6 73.7%  
Effective tax rate %-14.314.3 -99.8%   
Net profit margin %5.49.3 57.7%  
BALANCE SHEET DATA
Current assets Rs m18,877108,141 17.5%   
Current liabilities Rs m11,89638,322 31.0%   
Net working cap to sales %33.945.9 73.9%  
Current ratio x1.62.8 56.2%  
Inventory Days Days3697 37.0%  
Debtors Days Days19874 265.9%  
Net fixed assets Rs m9,861109,411 9.0%   
Share capital Rs m3411,610 21.2%   
"Free" reserves Rs m12,331140,682 8.8%   
Net worth Rs m16,139142,292 11.3%   
Long term debt Rs m4,70636,621 12.8%   
Total assets Rs m33,146228,606 14.5%  
Interest coverage x1.616.3 9.9%   
Debt to equity ratio x0.30.3 113.3%  
Sales to assets ratio x0.60.7 93.3%   
Return on assets %8.16.7 121.7%  
Return on equity %6.910.0 68.9%  
Return on capital %12.310.0 123.5%  
Exports to sales %21.432.8 65.2%   
Imports to sales %15.20-   
Exports (fob) Rs m4,40249,883 8.8%   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40251,691 8.5%   
Fx outflow Rs m3,18421,033 15.1%   
Net fx Rs m1,21930,658 4.0%   
CASH FLOW
From Operations Rs m2,43714,628 16.7%  
From Investments Rs m-6,265-8,540 73.4%  
From Financial Activity Rs m2,490-3,855 -64.6%  
Net Cashflow Rs m-1,3372,431 -55.0%  

Share Holding

Indian Promoters % 82.7 16.0 516.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 4.3 12.2 35.2%  
FIIs % 5.5 23.7 23.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 7.5 26.2 28.6%  
Shareholders   10,665 161,166 6.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, IPO Buzz, and Top Stocks in Action Today(Pre-Open)

On Wednesday, share markets in India witnessed volatile trading activity and ended on a negative note. Among sectoral indices, FMCG stocks and realty stocks lost the most.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - AJANTA PHARMA COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS